Analysis of Patients with NET G1/G2 Neuroendocrine Tumors of the Small Intestine in the Course of Carcinoid Heart Disease-A Retrospective Study

被引:1
|
作者
Konsek-Komorowska, Sonia J. J. [1 ]
Peczkowska, Mariola [2 ]
Kolasinska-Cwikla, Agnieszka D. D. [3 ]
Cichocki, Andrzej [3 ]
Konka, Marek [2 ]
Roszkowska-Purska, Katarzyna [3 ]
Cwikla, Jaroslaw B. [1 ,4 ]
机构
[1] Univ Warmia & Mazury, Sch Med, Dept Cardiol & Internal Med, Coll Med, PL-10082 Olsztyn, Poland
[2] Cardinal Stefan Wyszynski Natl Inst Cardiol, PL-04628 Warsaw, Poland
[3] Maria Sklodowska Curie Natl Res Inst Oncol, PL-02034 Warsaw, Poland
[4] Diagnost & Therapeut Ctr Gammed, PL-02351 Warsaw, Poland
关键词
carcinoid heart disease; carcinoid syndrome; neuroendocrine neoplasms of the small intestine; overall survival; primary tumor resection; POLISH NETWORK; GUIDELINES; NEOPLASMS; CLASSIFICATION; PROGRESSION; DIAGNOSIS; PROGNOSIS; MIDGUT;
D O I
10.3390/jcm12030790
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Neuroendocrine neoplasms of the small intestine (SI-NENs) are one of the most commonly recognized gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). Carcinoid heart disease (CHD) is the primary cause of death in patients with the carcinoid syndrome (CS). The aim of this retrospective study was to evaluate possible factors impacting upon overall survival (OS) in subjects with both neuroendocrine tumors (NETs) G1/G2 of the small intestine (SI-NET) and CHD. Enrolled in our study of 275 patients with confirmed G1/G2 SI-NET, were 28 (10%) individuals with CHD. Overall survival was assessed using the Kaplan-Meier method. The Cox-Mantel test was used to determine how OS varied between groups. A Cox proportional hazards model was used to conduct univariate analyses of predictive factors for OS and estimate hazard ratios (HRs). Of the 28 individuals with confirmed carcinoid heart disease, 12 (43%) were found to have NET G1 and 16 (57%) were found to have NET G2. Univariate analysis revealed that subjects with CHD and without resection of the primary tumor had a lower OS. Our retrospective study observed that patients who presented with CHD and without resection of primary tumor had worse prognosis of survival. These results suggest that primary tumors may need to be removed when feasible, but further research is needed. However, no solid recommendations can be issued on the basis of our single retrospective study.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Value of diffusion-weighted magnetic resonance imaging in predicting World Health Organization grade in G1/G2 pancreatic neuroendocrine tumors
    Guo, Chuangen
    Zhuge, Xiaoling
    Chen, Xiao
    Wang, Zhongqiu
    Xiao, Wenbo
    Wang, Qidong
    ONCOLOGY LETTERS, 2017, 13 (06) : 4141 - 4146
  • [42] Carcinoid heart disease in patients with advanced small-intestinal neuroendocrine tumors and carcinoid syndrome: a retrospective experience from two European referral centers
    Algeri, L.
    Falkman, L.
    Spada, F.
    Frassoni, S.
    Bagnardi, V.
    Boselli, S.
    Cardinale, D.
    Zanobini, M.
    Crona, J.
    Benini, L.
    Tamayo, D.
    Mazzon, C.
    Gervaso, L.
    Cella, C. A.
    Zampino, M. G.
    Ciardiello, D.
    Russo, A.
    Badalamenti, G.
    Welin, S.
    Fazio, N.
    ESMO OPEN, 2024, 9 (11)
  • [43] Predictive value of preoperative MRI features for the Ki-67 index in well-differentiated G1/G2 pancreatic neuroendocrine tumors
    Sun, Haitao
    Zhang, Shilong
    Liu, Kai
    Zhou, Jianjun
    Wang, Xingxing
    Shen, Tingting
    Wang, Xiaolin
    ACTA RADIOLOGICA, 2019, 60 (11) : 1394 - 1404
  • [44] REAL-WORLD RESOURCE USE AND COSTS OF CARCINOID HEART DISEASE IN PATIENTS WITH NEUROENDOCRINE TUMORS: A RETROSPECTIVE SWEDISH STUDY
    Bjorstad, A.
    Marlow, T.
    Lesen, E.
    Bollano, E.
    Marteau, F.
    Gabriel, S.
    Welin, S.
    Fcuilly, M.
    VALUE IN HEALTH, 2017, 20 (09) : A552 - A552
  • [45] Novel scoring system for recurrence risk classification of surgically resected G1/2 pancreatic neuroendocrine tumors - Retrospective cohort study
    Zou, Siyi
    Jiang, Yu
    Wang, Weishen
    Zhan, Qian
    Deng, Xiaxing
    Shen, Baiyong
    INTERNATIONAL JOURNAL OF SURGERY, 2020, 74 : 86 - 91
  • [46] Efficacy of lenvatinib in patients with advanced pancreatic (panNETs) and gastrointestinal (giNETs) grade 1/2 (G1/G2) neuroendocrine tumors: Results of the international phase II TALENT trial (GETNE 1509)
    Capdevila, J.
    Fazio, N.
    Lopez, C.
    Teule, A.
    Valle, J. W.
    Tafuto, S.
    Custodio, A.
    Reed, N.
    Raderer, M.
    Grande, E.
    Garcia-Carbonero, R.
    Jimenez Fonseca, P.
    Alonso, V.
    Antonuzzo, L.
    Spallanzani, A.
    Berruti, A.
    Sevilla Garcia, I.
    La Casta, A.
    Hernando, J.
    Ibrahim, T.
    ANNALS OF ONCOLOGY, 2018, 29 : 467 - 467
  • [47] Ki-67 Index of 5% is Better Than 2% in Stratifying G1 and G2 of the World Health Organization Grading System in Pancreatic Neuroendocrine Tumors
    Gao, Shao-Wei
    Huang, Chen-Song
    Huang, Xi-Tai
    Chen, Liu-Hua
    Chen, Wei
    Cai, Jian-Peng
    Yin, Xiao-Yu
    PANCREAS, 2019, 48 (06) : 795 - 798
  • [48] The Value of Somatostatin Receptor Scintigraphy (SRS) in Patients with NETG1/G2 Neuroendocrine Neoplasms of the Small Intestine (SI-NENs)
    Konsek, S. J.
    Kolasinska-Cwikla, A. D.
    Lewczuk, A.
    Kidd, M.
    Buscombe, J. R.
    Bodei, L.
    Cichocki, A.
    Roszkowska-Purska, K.
    Cwikla, J. B.
    Modlin, I. M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S468 - S469
  • [49] Usefulness of Somatostatin Receptor Scintigraphy (SRS) in Patients with NETG1/G2 Neuroendocrine Neoplasms of the Small Intestine (SI-NENs)
    Konsek, S.
    Kolasinska-Cwikla, A.
    Cwikla, J.
    Kidd, M.
    Buscombe, J. R.
    Bodei, L.
    Cichocki, A.
    Roszkowska-Purska, K.
    Lewczuk-Myslinska, A.
    Modlin, I
    NEUROENDOCRINOLOGY, 2019, 108 : 215 - 215
  • [50] CLEC3A, MMP7, and LCN2 as novel markers for predicting recurrence in resected G1 and G2 pancreatic neuroendocrine tumors
    Miki, Masami
    Oono, Takamasa
    Fujimori, Nao
    Takaoka, Takehiro
    Kawabe, Ken
    Miyasaka, Yoshihiro
    Ohtsuka, Takao
    Saito, Daisuke
    Nakamura, Masafumi
    Ohkawa, Yasuyuki
    Oda, Yoshinao
    Suyama, Mikita
    Ito, Tetsuhide
    Ogawa, Yoshihiro
    CANCER MEDICINE, 2019, 8 (08): : 3748 - 3760